Comparative Pharmacology
Head-to-head clinical analysis: TRILEPTAL versus VIGABATRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRILEPTAL versus VIGABATRIN.
TRILEPTAL vs VIGABATRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trileptal (oxcarbazepine) stabilizes neuronal membranes by blocking voltage-sensitive sodium channels, thereby inhibiting repetitive firing of action potentials. It also modulates high-voltage-activated calcium channels and increases potassium conductance.
Irreversibly inhibits GABA transaminase, increasing brain GABA levels.
Adults: 600 mg orally twice daily initially; titrate by 600 mg/day every week. Maintenance: 600-1200 mg twice daily.
Adults: 500 mg orally twice daily; may increase by 500 mg/day every 7 days up to 1500 mg twice daily. For refractory complex partial seizures, maximum 3000 mg/day.
None Documented
None Documented
Parent oxcarbazepine: 1.3–2.3 hours; active metabolite MHD: 8–11 hours (monohydroxy derivative); clinically, the long MHD half-life supports twice-daily dosing.
Clinical Note
moderateVigabatrin + Venlafaxine
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Venlafaxine."
Clinical Note
moderateVigabatrin + Nefazodone
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Nefazodone."
Clinical Note
moderateVigabatrin + Stiripentol
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Stiripentol."
Clinical Note
moderateVigabatrin + Clomipramine
5-8 hours in young adults; 12-17 hours in elderly; prolonged with renal impairment.
Renal excretion is the primary route; 95% of the dose is excreted in urine (79% as MHD, 20% as MHD conjugates, <1% as unchanged oxcarbazepine), and 4% in feces.
Renal: ~80% unchanged in urine; fecal: <5%.
Category C
Category A/B
Anticonvulsant
Anticonvulsant
"The risk or severity of adverse effects can be increased when Vigabatrin is combined with Clomipramine."